Bayer AG forecast a third straight year of falling profit as the German company struggles with mass litigation in the US, slumping prices for agriculture products and fresh competition for some of its best-selling medicines.
Core earnings will probably fall to between €4.50 ($4.78) and €5 a share on a constant-currency basis, the company said in a statement Wednesday. That’s down from €5.05 last year and compares with analysts’ average estimate of €4.61.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.